Acute pharyngotonsillitis is a common disease, mainly characterized by a sore throat. The diagnosis is usually performed on the clinical ground, and antibiotic therapy is frequently used in clinical practice on an empirical basis. Antibiotics frequently induce intestinal and respiratory dysbiosis associated with slow recovery. Therefore, probiotics are commonly prescribed in patients treated with antibiotics to restore the physiological microbiota. The current clinical experience was conducted in patients with acute pharyngotonsillitis and treated with antibiotics. All patients were treated with antibiotics and Abincol@ for two weeks, then a subgroup (ratio 1:1) took a one-month course of Abincol Immuno (R) (Group A), the other patients served as control (Group B). Patients were evaluated at baseline (T0), at the end of antibiotictreatment (T1), at the end of the Abincol Immuno (R) course (T2), and at the end of 4-month follow-up (T3). Globally, 922 outpatients (mean age 46 years) were enrolled: 452 (49%) in Group A and 470 (51%) in Group B. At T2, Group A patients had a lower frequency of all symptoms. Both nutraceuticals were well tolerated. In conclusion, the present clinical experience demonstrated that immune manipulation with this innovative multi-component product might be considered an effective and safe therapeutic option in managing patients with acute pharyngotonsillitis and treated with antibiotics.

Probiotics, zinc, inulin, and vitamin D as an ancillary treatment for patients with acute pharyngotonsillitis

P Viola;G. Chiarella
2022-01-01

Abstract

Acute pharyngotonsillitis is a common disease, mainly characterized by a sore throat. The diagnosis is usually performed on the clinical ground, and antibiotic therapy is frequently used in clinical practice on an empirical basis. Antibiotics frequently induce intestinal and respiratory dysbiosis associated with slow recovery. Therefore, probiotics are commonly prescribed in patients treated with antibiotics to restore the physiological microbiota. The current clinical experience was conducted in patients with acute pharyngotonsillitis and treated with antibiotics. All patients were treated with antibiotics and Abincol@ for two weeks, then a subgroup (ratio 1:1) took a one-month course of Abincol Immuno (R) (Group A), the other patients served as control (Group B). Patients were evaluated at baseline (T0), at the end of antibiotictreatment (T1), at the end of the Abincol Immuno (R) course (T2), and at the end of 4-month follow-up (T3). Globally, 922 outpatients (mean age 46 years) were enrolled: 452 (49%) in Group A and 470 (51%) in Group B. At T2, Group A patients had a lower frequency of all symptoms. Both nutraceuticals were well tolerated. In conclusion, the present clinical experience demonstrated that immune manipulation with this innovative multi-component product might be considered an effective and safe therapeutic option in managing patients with acute pharyngotonsillitis and treated with antibiotics.
2022
acute pharyngotonsillitis
antibiotic therapy
dysbiosis
probiotics
zinc
inulin
vitamin D
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/79868
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact